Ignite Creation Date:
2024-05-06 @ 12:31 PM
Last Modification Date:
2024-10-26 @ 1:00 PM
Study NCT ID:
NCT03786107
Status:
TERMINATED
Last Update Posted:
2021-05-19
First Post:
2018-12-20
Brief Title:
HER-Seq A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
Sponsor:
Organization:
Puma Biotechnology Inc
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
False
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
SAMPLES_WITH_DNA
Bio Spec Description:
Circulating tumor DNA from plasma will be collected from eligible participants ERBB2 HER2 gene exons 8 and 17-24 will be sequenced by next generation sequencing NGS at a central laboratory
Enrollment Count:
1583
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Cohort |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 52908 |
Who Masked List: